Last 46 quarters of trend data · Healthcare · Drug Manufacturers - General
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Johnson & Johnson's quarterly P/E stands at 21.2x, down 41.7% year-over-year — suggesting improving earnings relative to price. EV/EBITDA has compressed 8.6% YoY to 13.1x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 39.45 | 21.19 | 16.64 | 9.01 | 25.72 | 36.35 | 18.93 | 29.51 | 23.46 | 3.81 | 21.11 | — | 33.20 |
| — | -41.7% | -12.1% | -69.5% | +9.6% | +853.2% | -10.3% | — | -29.3% | -84.3% | -15.3% | — | +37.4% | |
| P/S Ratio | 6.20 | 4.55 | 3.88 | 4.53 | 3.91 | 4.36 | 3.94 | 4.49 | 4.45 | 4.65 | 5.05 | 4.83 | 4.96 |
| — | +4.3% | -1.5% | +0.8% | -12.2% | -6.2% | -21.9% | -7.0% | -10.3% | -14.5% | +1.3% | -4.7% | +7.8% | |
| P/B Ratio | 7.76 | 5.51 | 4.70 | 5.08 | 4.92 | 5.59 | 4.95 | 5.49 | 5.54 | 5.58 | 5.69 | 5.70 | 6.13 |
| — | -1.4% | -5.1% | -7.5% | -11.1% | +0.2% | -13.0% | -3.7% | -9.6% | -4.3% | -9.3% | -10.4% | -0.7% | |
| P/FCF | 27.74 | 13.02 | 37.17 | 29.48 | 18.19 | 17.14 | 19.00 | 33.72 | 15.18 | 15.22 | 35.53 | 42.17 | 31.26 |
| — | -24.1% | +95.6% | -12.6% | +19.8% | +12.6% | -46.5% | -20.0% | -51.4% | -25.3% | +40.0% | +19.7% | +18.2% | |
| EV / EBITDA | 19.09 | 13.07 | 11.45 | 12.72 | 15.89 | 14.30 | 10.98 | 12.13 | 15.06 | 12.69 | 13.84 | 13.46 | 21.90 |
| — | -8.6% | +4.3% | +4.8% | +5.5% | +12.8% | -20.7% | -9.9% | -31.3% | -18.1% | -9.1% | -14.7% | +16.3% | |
| EV / EBIT | 25.42 | 15.44 | 14.74 | 7.42 | 22.65 | 28.86 | 15.40 | 25.37 | 19.51 | 18.83 | 17.59 | — | 28.40 |
| — | -46.5% | -4.3% | -70.8% | +16.1% | +53.3% | -12.5% | — | -31.3% | -13.6% | -17.4% | — | +16.8% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Johnson & Johnson's operating margin was 29.6% in Q3 2025, up 0.9 pp QoQ and up 6.1 pp YoY. The trailing four-quarter average of 26.0% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 69.1% | 69.6% | 67.9% | 66.4% | 68.3% | 69.0% | 69.4% | 69.6% | 68.2% | 69.1% | 70.0% | 68.0% | 67.2% |
| — | +0.8% | -2.2% | -4.5% | +0.2% | -0.1% | -0.8% | +2.3% | +1.5% | -0.1% | +4.4% | +0.6% | -1.0% | |
| Operating Margin | 24.9% | 29.6% | 28.7% | 28.8% | 17.1% | 23.5% | 29.7% | 29.3% | 21.5% | 29.0% | 29.5% | 29.9% | 16.5% |
| — | +25.9% | -3.3% | -1.9% | -20.8% | -19.1% | +0.4% | -1.9% | +30.7% | +2.5% | +9.7% | +14.5% | -8.7% | |
| Net Margin | 15.8% | 21.5% | 23.3% | 50.2% | 15.2% | 12.0% | 20.9% | 15.2% | 18.9% | 121.9% | 23.9% | -0.3% | 14.8% |
| — | +79.1% | +11.7% | +230.0% | -19.5% | -90.2% | -12.7% | +4776.6% | +27.5% | +446.8% | +19.3% | -101.5% | -22.2% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 20.1% | 6.5% | 7.1% | 14.7% | 4.8% | 3.8% | 6.6% | 4.7% | 5.8% | 35.3% | 7.0% | -0.1% | 4.6% |
| — | +71.8% | +6.8% | +213.5% | -16.2% | -89.2% | -5.2% | +5192.7% | +24.4% | +497.0% | +9.6% | -101.3% | -29.2% | |
| ROA | 8.1% | 2.7% | 2.9% | 5.9% | 1.9% | 1.5% | 2.7% | 1.9% | 2.4% | 14.6% | 2.7% | -0.0% | 1.9% |
| — | +77.9% | +7.8% | +206.9% | -21.1% | -89.7% | +0.0% | +5501.1% | +25.0% | +475.8% | -1.8% | -101.2% | -25.9% | |
| ROIC | 20.7% | 4.9% | 5.0% | 5.4% | 3.4% | 4.5% | 6.0% | 6.1% | 4.4% | 5.1% | 4.6% | 4.5% | 2.9% |
| — | +7.6% | -16.0% | -11.8% | -22.6% | -10.8% | +29.3% | +35.4% | +48.8% | +16.0% | -6.6% | -6.5% | -21.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Johnson & Johnson's Debt/EBITDA ratio is 5.2x, down from 5.8x last quarter — elevated, raising questions about debt serviceability. Debt/Equity has declined for 3 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.51 | 0.58 | 0.65 | 0.67 | 0.51 | 0.51 | 0.58 | 0.48 | 0.43 | 0.42 | 0.60 | 0.75 | 0.52 |
| — | +13.4% | +11.5% | +39.3% | +20.1% | +21.3% | -2.8% | -35.7% | -17.4% | -2.2% | +39.8% | +68.3% | +13.2% | |
| Debt / EBITDA | 1.24 | 5.16 | 5.80 | 6.47 | 6.39 | 5.02 | 4.92 | 4.16 | 4.55 | 3.73 | 5.50 | 6.51 | 6.98 |
| — | +2.8% | +18.0% | +55.7% | +40.4% | +34.6% | -10.6% | -36.1% | -34.9% | -14.5% | +38.6% | +54.9% | +30.7% | |
| Current Ratio | 1.11 | 1.07 | 1.01 | 1.26 | 1.11 | 1.03 | 1.07 | 1.17 | 1.16 | 1.21 | 1.12 | 1.07 | 0.99 |
| — | +4.4% | -6.2% | +7.5% | -3.9% | -15.0% | -4.1% | +9.7% | +16.6% | -15.5% | -21.5% | -23.4% | -26.5% | |
| Quick Ratio | 0.86 | 0.80 | 0.76 | 1.03 | 0.86 | 0.79 | 0.85 | 0.94 | 0.91 | 0.96 | 0.88 | 0.85 | 0.81 |
| — | +1.3% | -10.4% | +10.5% | -5.6% | -18.0% | -3.8% | +9.6% | +13.3% | -18.5% | -24.7% | -25.0% | -27.9% | |
| Interest Coverage | 29.34 | 394.22 | 22.11 | 30.88 | 28.04 | 27.35 | 24.66 | 40.47 | 30.51 | 32.28 | 29.30 | 29.46 | 22.06 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 46 years · Updated daily
Deep dive into JNJ consensus models and risk factors.
Wall Street verdict, signals, and target summaries.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying JNJ stock.
Johnson & Johnson's current P/E is 39.4x. The average P/E over the last 4 quarters is 18.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Johnson & Johnson's current operating margin is 24.9%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Johnson & Johnson's business trajectory between earnings reports.